Inflammation, Diabetes, Ethnicity and Obesity Cohort

NCT03022682 | Recruiting

• 1 other identifier: 14-14248
• Study Type: observational
• Target: 350
• Locations: 1 country
• Sites: 1

Brief Summary

Obesity affects over one third of US adults (\>72 million, with BMI ≥30 kg/m2), and the proportion of US adults with BMI ≥40 kg/m2 has doubled in the last 20 years. Obesity is associated with increased mortality through its linkage to comorbidities including diabetes, hypertension, dyslipidemia, osteoarthritis, sleep apnea and psychosocial disturbances. Given its prevalence, impact on morbidity and mortality, and economic cost, limiting the spread of obesity and its consequences is one of the most important problems of our time. In this proposed study, investigators will recruit participants from a wide range of body mass index (BMI), ethnicity and Diabetes risk to collect data and blood, stool and adipose tissue samples in the San Francisco bay area.

Conditions

Obesity; Diabetes Mellitus; Pre Diabetes

Keywords

ethnicity; inflammation; obesity; diabetes

Outcome Measures

Primary Outcomes (1)

• Complete recruitment of IDEO cohort participants to spur novel and creative interactions between investigators that have transformative potential in obesity research.

  Number of biological samples collected

  7 years

Secondary Outcomes (1)

• Adipose tissue inflammation and fibrosis

  7 years

Study Arms (1)

IDEO Cohort

Adipose tissue samples are collected from all participants, including aspirational subcutaneous biopsies from nonsurgical participants and excisional biopsies, performed intra-operatively by surgical collaborators as required. Participants also undergo anthropometric measurements, stool collection, blood sample collection for circulating blood cells, serum, and plasma. Dual-energy x-ray absorptiometry (DXA) scan for amount and distribution of body fat as well as bone density is performed. Study participants complete validated questionnaire inventories to measure bio-behavioral issues such as depression, stress, health locus of control, and dietary habits.

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

IDEO Cohort participants

You may qualify if:

• Patients with either diabetes type 2 or the metabolic syndrome will be included in the cohort.

You may not qualify if:

• Participants with chronic kidney disease (\> stage 4)
• Autoimmune/inflammatory disease (e.g., Lupus, Ulcerative Colitis, etc.)
• Unstable angina, New York (NY) class III or IV congestive heart failure or myocardial infarction within 3 months of entry
• Clinically significant liver disease (e.g. Cirrhosis or liver failure)
• Weight \> 450 pounds (DXA scan weight limit)
• History of organ transplant
• Treatment with chemotherapy or radiation therapy at the time of enrollment in study.
• Poorly controlled asthma (participants requiring inhaled glucocorticoids and/or oral glucocorticoids)
• Current nasal corticosteroid use (within the past month)
• Excessive alcohol or substance abuse
• Current use of anabolic steroids or testosterone for bodybuilding purposes. Testosterone use is permitted if prescribed for hypogonadism and dose stable for the past 6 months.
• Patients actively enrolled in interventional trials involving investigational agents
• Pregnant or breast-feeding women
• Appears unlikely or unable to participate in the required study procedures as assessed by the investigator, study coordinator or designee.
• History of abnormal clotting

Sponsors & Collaborators

• University of California, San Francisco: lead

Study Sites (1)

University of California San Francisco

San Francisco, California, 94143, United States

RECRUITING

Related Publications (2)

• Alba DL, Abdellatif A, Choi MK, Brown Mayfield SM, Pham TAT, Berrios DI, Rodriguez AE, Ewing M, Figueroa TR, Gonzalez-Vargas J, Zhang N, An Z, Bu D, Deeks SG, Scherer PE, Hunt PW, Koliwad SK. A distinct form of fat fibrosis is linked to insulin resistance in people with HIV. JCI Insight. 2026 Jun 30;11(15):e195922. doi: 10.1172/jci.insight.195922. eCollection 2026 Aug 10.

  PMID: 42378059 DERIVED

• Koppel N, Bisanz JE, Pandelia ME, Turnbaugh PJ, Balskus EP. Discovery and characterization of a prevalent human gut bacterial enzyme sufficient for the inactivation of a family of plant toxins. Elife. 2018 May 15;7:e33953. doi: 10.7554/eLife.33953.

  PMID: 29761785 DERIVED

Related Links

• Koliwad Lab

Biospecimen

Retention: SAMPLES WITH DNA

Serum, plasma, Adipose tissue, stool

MeSH Terms

Conditions

Obesity; Diabetes Mellitus; Glucose Intolerance; Inflammation

Condition Hierarchy (Ancestors)

Overweight; Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases; Hyperglycemia; Pathologic Processes

Study Officials

• Suneil Koliwad, MD,PhD

  University of California, San Francisco

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 12, 2017
• First Posted: January 16, 2017
• Study Start: February 1, 2015
• Primary Completion (Estimated): December 1, 2029
• Study Completion (Estimated): December 1, 2029
• Last Updated: September 8, 2026

Record last verified: 2026-09

Locations

US (1)